QF
AKTX

QVT Financial’s Akari Therapeutics AKTX Stock Holding History

QVT Financial’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-165
Closed -$531K – 71
2017
Q2 		$531K Sell
165
-96
-37% -$759K 0.01% 71
2017
Q1 		$1.89M Sell
261
-62
-19% -$347K 0.06% 70
2016
Q4 		$1.45M Sell
323
-7
-2% -$45.2K 0.04% 82
2016
Q3 		$1.83M Hold
330
– – 0.07% 67
2016
Q2 		$2.91M Hold
330
– – 0.2% 65
2016
Q1 		$3.21M Hold
330
– – 0.2% 73
2015
Q4 		$3.64M Buy
+330
New +$4.9M 0.2% 70

Other funds holding AKTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

QVT Financial's AKTX Position: Q3 2017 in Review

QVT Financial sold out of Akari Therapeutics (AKTX) in Q3 2017, closing a stake of 165 shares — an estimated $531K sold.

QVT Financial first reported a position in AKTX in Q4 2015 and held it in 7 quarters. The position peaked at $3.64M in Q4 2015. 12 funds tracked by Wall St. Rank hold AKTX as of Q3 2017.

  • QVT Financial reported no remaining Akari Therapeutics position as of Q3 2017 after selling out during the quarter.
  • QVT Financial sold 165 Akari Therapeutics shares in Q3 2017, an estimated $531K.
  • QVT Financial first reported a position in Akari Therapeutics in Q4 2015 and held it in 7 quarters.
  • QVT Financial's Akari Therapeutics position peaked at $3.64M in Q4 2015.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2017.

Based on QVT Financial's 13F filing for Q3 2017, filed 14 Nov 2017.